Impaired Hepatic Function clinical trials

Explore recruiting impaired hepatic function clinical trials.

Recruiting impaired hepatic function studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Impaired Hepatic Function trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics Of Mavodelpar In Subjects With Impaired Hepatic Function

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

Slovakia, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

Greece

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Study to Assess the Pharmacokinetics of Rifaximin Soluble Solid Dispersion (SSD) Formulation in Adult Subjects with Impaired Hepatic Function

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multiple Dose Pharmacokinetic Study of AMX0035 in Participants with Impaired Hepatic Function and in Healthy Participants

Bulgaria

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function

Germany, Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

Impaired Hepatic Function trials by city

Impaired Hepatic Function in Toronto Impaired Hepatic Function in Vancouver Impaired Hepatic Function in Montreal Impaired Hepatic Function in Calgary Impaired Hepatic Function in Edmonton Impaired Hepatic Function in Ottawa Impaired Hepatic Function in Winnipeg Impaired Hepatic Function in Quebec City Impaired Hepatic Function in Hamilton Impaired Hepatic Function in Kitchener Impaired Hepatic Function in London Impaired Hepatic Function in Halifax Impaired Hepatic Function in New York Impaired Hepatic Function in Los Angeles Impaired Hepatic Function in Chicago Impaired Hepatic Function in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease